RESEARCH CENTER – CLINICAL TRIALS

ACCESS TO THE LATEST
TREATMENTS

Oregon Urology Institute is committed to advancing the standard of care in treating urological disorders and cancers. To achieve this, we are deeply involved in research at our urology clinic. This gives our patients access to experimental procedures and treatments that wouldn’t otherwise be available.

If you’d like to join one of the trials at our urology clinic, your doctor can help determine if you’re a candidate. Qualified candidates will be informed about potential risks and benefits. Our clinical trial participants are carefully monitored, and you can opt out at any time.

CURRENTLY
ENROLLING

Here are trials we’re currently conducting at our urology clinic. Ask your doctor for more information if you’re interested in participating.

PSMA DC – Novartis D

Study Type: Interventional (Clinical Trial)
Study Design:
- Estimated Enrollment: 450 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Official Title: An International, Prospective, Open-label, Multicenter, Randomized Phase Ill Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT05939414

PSMACare – Novartis B

Study Type: Interventional (Clinical Trial)
Study Design:
- Estimated Enrollment: 120 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Official Title: An International Prospective Open-label, Multi-center, Randomized, non-comparative Phase II Study of lutetium (177Lu) vipivotide tetraxetan (AAA617) alone and lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with Androgen Receptor Pathway Inhibitors in patients with PSMA PET scan positive Castration-Resistant Prostate Cancer
Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT05849298

CG Oncology - PIVOT-006

Study Type: Interventional (Clinical Trial)
Study Design:
- Estimated Enrollment: 364 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Official Title: A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06111235

Debio 4228-201

Study Type: Interventional (Clinical Trial)
Study Design:
- Estimated Enrollment: 60 participants
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
Official Title: A Phase 2, randomized, open-label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with locally advanced/metastatic prostate cancer
Clinicaltrials.gov link: https://clinicaltrials.gov/study/NCT06395753

GIAnomics

Study Type: Observational (Genetic Testing)
Study Design:
- Estimated Enrollment: 3000 participants
- Allocation: N/A
- Intervention Model: N/A
- Masking: None
- Primary Purpose: Diagnosis and Risk Assessment
Official Title: Genetic Susceptibility and Management of Chronic Disease
Link to sponsor page: https://www.genlabus.com/2020/03/12/designer-genomics-international-selects-genetics-institute-of-america-as-irb-approved-laboratory-for-inflammasome-study/

ONGOING STUDIES
NOT ENROLLING

Bladder Cancer-KN676

Study Type: Interventional (Clinical Trial)

Study Design:

Estimated Enrollment: 1045 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Official Title: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Either Persistent or Recurrent Following BCG Induction or That is Naïve to BCG Treatment (KEYNOTE-676)

For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–ATLAS

Study Type: Interventional

Study Design:

Allocation: Randomized
Actual Enrollment: 1503 Participants
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Official Title: ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy.

For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–DAROL

Study Type: Observational

Study Design:

Observational Model: Cohort
Time Perspective: Prospective
Estimated Enrollment: 1000 participants

Official Title:Darolutamide Observational Study in Non-metastatic Castration-resistant
For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–EMBARK

Study Type: Interventional

Study Design:

Actual Enrollment: 1068 participants
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy)

For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–PRIMORDIUM

Study Type: Interventional

Study Design:

Enrollment Estimate: 412 participants
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Official Title: A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–SAFELY

Study Type: Observational

Study Design:

Observational Model: Cohort
Time Perspective: Prospective
Estimated Enrollment: 600 participants
Target Follow-Up Duration: 10 Years
Official Title: A Multi-center, Prospective Active Surveillance Registry Trial Assessing the Performance of a Non-invasive Immunogenomic Blood Test for Indolent Prostate Cancer Disease Management.

For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–ULYSSES

Study Type:
Interventional

Study Design:
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title:
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer

For more information on this study, visit clinicaltrials.gov

URETHRAL STRICTURE–ROBUST III

Study Type: Interventional

Study Design:

Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment

Official Title:

ROBUST III – Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease – A Randomized Control Trial

For more information on this study, visit clinicaltrials.gov

PROSTATE CANCER–TAK-RAD

Study Type:
Interventional

Study Design:

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Official Title: A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
For more information on this study, visit clinicaltrials.gov